Kilitch Drugs (India) Ltd
Kilitch Drugs (India) Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
- Revenue
- ₹50Cr
- Net profit
- ₹1Cr
- Margin
- 13.3%
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Kilitch Drugs (India) Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue/Sales for the quarter ended 30th September 2026:. EBITDA for the quarter ended 30th September 2026 is Rs. 908.85 Lakhs, up 252% year-on-year (Q2 FY26: Rs. 258.14 Lakhs).
From Kilitch Drugs (India) Ltd's Q2 FY27 earnings-call transcript · updated 7 Nov 2026.
How did Kilitch Drugs (India)'s revenue grow in the September 2026 quarter?
- Revenue/Sales for the quarter ended 30th September 2026:
- Net Sales/Income from Operations: Rs. 5,021.50 Lakhs
- Other Income: Rs. 215.90 Lakhs
- Total Income: Rs. 5,237.40 Lakhs
- Year-on-year comparison (quarter ended 30th September 2025):
- Net Sales/Income from Operations: Rs. 4,392.45 Lakhs
- Other Income: Rs. 666.04 Lakhs
- Total Income: Rs. 5,558.49 Lakhs
- Year-on-year changes:
- Net Sales increased by Rs. 629.05 Lakhs (approx. 14.3%)
2 more points from Kilitch Drugs (India) Ltd's call on revenue
Create a free account to keep reading this call
What happened to Kilitch Drugs (India)'s margins in Q2 FY27?
See what Kilitch Drugs (India) Ltd said on profitability & margins — free account, 30 seconds.
What capex is Kilitch Drugs (India) planning?
- Capital work-in-progress as at 30th September 2026 stands at Rs. 14,001.93 Lakhs (Standalone and Consolidated Balance Sheets).
- Significant capital expenditure during the six months ended 30th September 2026 was Rs. 1,558.73 Lakhs (Standalone) and Rs. 1,807.99 Lakhs (Consolidated) shown under cash flow from investing activities.
- Investments appear focused on property, plant & equipment as part of expansion or enhancement efforts indicated by increased asset values.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Kilitch Drugs (India) raising money or cutting debt?
See what Kilitch Drugs (India) Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Kilitch Drugs (India)'s order book?
See what Kilitch Drugs (India) Ltd said on order book & pipeline — free account, 30 seconds.
Kilitch Drugs (India) Ltd — Quarterly revenue & net profit
Kilitch Drugs (India) Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 50 |
| Operating profit (EBITDA) | 7 |
| Operating margin | 13.3% |
| Profit before tax | 3 |
| Net profit (PAT) | 1 |
| EPS (₹) | 0.64 |
Source: Kilitch Drugs (India) Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹50 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Kilitch Drugs's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- NGL Fine Chem (Q2 FY27)
Consolidated: ₹15,870.73 lakhs . Key results statement takeaways from NGL Fine Chem Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Mangalam Drugs (Q2 FY27)
59% growth. Key results statement takeaways from Mangalam Drugs and Organics Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Astrazeneca Phar (Q2 FY27)
Year-on-year revenue growth for the quarter: Rs 7,291.0 million vs Rs 5,590.9 million, approximately 30.5% increase. Key results statement takeaways from Astraz
- Cohance Lifesciences Ltd (Q2 FY27)
Q2 FY27 revenue: INR 4,766 Mn, down 14.2% YoY (Page 8, 9) . Key investor presentation takeaways from Cohance Lifesciences Ltd's Q2 FY27 investor presentation —
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Kilitch Drugs (India) Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Kilitch Drugs (India) Ltd Q2 FY27 results?
Revenue/Sales for the quarter ended 30th September 2026:. EBITDA for the quarter ended 30th September 2026 is Rs. 908.85 Lakhs, up 252% year-on-year (Q2 FY26: Rs. 258.14 Lakhs).
What is Kilitch Drugs (India) Ltd share price analysis?
Kilitch Drugs (India) Ltd currently shows a neutral. The stock trades at a P/E of 22.7 with a market cap of ₹683 Cr. Investors should review the full earnings analysis for detailed insights.
Is Kilitch Drugs (India) Ltd planning capital expenditure?
Capital work-in-progress as at 30th September 2026 stands at Rs. 14,001.93 Lakhs (Standalone and Consolidated Balance Sheets).
Keep Kilitch Drugs (India) Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.